We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our efforts are currently focused on the fields of neurology, nephrology and rheumatology, areas of medicine which have significant unmet medical needs.
Our main product is H.P Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component.
We are currently supporting research in a number of rare conditions, where there is significant unmet need for treatment alternatives to standard therapies. We are also actively supporting research efforts to better understand disease processes and therapeutic mechanisms of action in conditions where Acthar might potentially play a role in treatment.
Prescriptions and Reimbursement Support
Questcor is dedicated to supporting patients at each step of the treatment process. With this in mind, Questcor personnel created the Acthar Support and Access Program (A.S.A.P.).
The Acthar Support & Access Program (A.S.A.P.) does the following:
- Contacts the patient's insurance company
- Investigates benefits and facilitates any prior authorizations if necessary
- Routes the prescription to the appropriate specialty pharmacy for fulfillment
- Ships Acthar and the necessary supplies next day for overnight delivery to the patient's home or alternate location under the appropriate temperature-controlled conditions
Acthar (repository corticotropin injection) is natural source ACTH (adrenocorticotropic hormone) in 16% gelatin to provide a prolonged release after intramuscular or subcutaneous injection.
Acthar is currently approved in the U.S. for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, for use during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis), as well as indicated for the treatment of several other diseases and disorders. For a full list of approved indications, please see the Acthar prescribing information.